Search Results

-9 via ERK1/2 signaling Published date September 1, 2023 Abstract "Neuropeptide FF (NPFF) belongs to NPFF treatment upregulates matrix metalloproteinase-9 (MMP-9) expression. Using the siRNA-mediated knockdown approach, we showed that the stimulatory effect of NPFF on MMP-9 expression In addition, blocking the activation of ERK1/2 signaling abolished the NPFF-induced MMP-9 expression This study provides evidence that NPFF stimulates EOC cell invasion by upregulating MMP-9 expression

Sponsors GPCR Retreat Program < Back to schedule Coffee Break 5 Date & Time Saturday, November 4th / 9:

Committee Sponsors GPCR Retreat Program < Back to schedule Board Meeting Date & Time Friday, November 3rd / 9:

In her spare time, Elva likes to run in the mountains, play with Tilly (a 9-year old retired greyhound

Structure-based discovery of functionally selective 5-HT1A receptor agonists Date & Time Saturday, November 4th / 9:

Cannabinoid compounds to augment L-DOPA treatment in Parkinson's Disease Date & Time Friday, November 3rd / 9:

Patients with Elevated ß2-Adrenergic Receptor Autoantibodies-An Interim Report Published date October 9,

Functional Selectivity to Investigate Metabolic Disease Pathophysiology Date & Time Friday, November 3rd / 9:

evaluated autoantibodes were significantly higher in Long-COVID compared to the 2 other groups (p = 2.1*10-9)

(Rgs5-KO) mice and RGS5 overexpression or knockdown in VSMCs in vivo by adeno-associated virus type 9

Single-cell RNA sequencing on long-bone stromal cells of 9-wk-old male ColI(2.3)+/Rs1+ mice and littermate

SF mutations (SRSF2, SF3B1) had a higher CR/CRi rate (50%) compared to those without SF mutations (9%

❄ Dec 9 - 15, 2024 Read More December 12, 2024 GPCR News Flash! Top Updates You Can't-Miss! ) promotes pressure overload-induced heart failure Read More GPCR Activation and Signaling December 9,

impact of different salvage strategies in an international cohort of 139 patients (n = 130 ide-cel, n = 9

Context-dependent ciliary regulation of hedgehog pathway repression in tissue morphogenesis Published date November 9,

. - Yamina will send an invite for a follow-up meeting with Arthur next Saturday at 9 PM. - Arthur and

. - Yamina will send an invite for a follow-up meeting with Arthur next Saturday at 9 PM. - Arthur and

, or reliability of any content made available in connection with third-party websites or services. 9.

Dr. GPCR Podcast << Back to podcast list Dr. Yamina Berchiche About Dr. Yamina Berchiche Dr. Yamina A. Berchiche is the founder of Dr. GPCR, an ecosystem designed to bring together stakeholders interested in using G-Protein Coupled Receptors (GPCRs) that control virtually everything in the body as drug targets. The mission of Dr. GPCR is to accelerate GPCR drug discovery by sharing the latest research and technology advances in the field and providing exposure to scientists through the Dr. GPCR podcast. Dr. Berchiche obtained her Master’s and Ph.D. in Biochemistry at the University of Montreal in Canada before training at Rockefeller University in New York and the National Institutes of Health in Bethesda, Maryland. She developed expertise over the past two decades studying structure/function relationships of GPCRs using live-cell bioluminescence resonance energy transfer (BRET). Her work focused on chemokine receptors, members of the GPCR family that control cell movement in the body. Dr. Yamina Berchiche on the web Website LinkedIn Facebook Twitter ResearchGate PubMed Google Scholar Dr. GPCR Ecosystem Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Dr. GPCR Podcast << Back to podcast list Brian Shoichet About Dr. Brian Shoichet BSc in Chemistry from MIT, Ph.D. with Tack Kuntz at UCSF; Postdoc with Brian Matthews in protein stability-activity tradeoffs, crystallography; started my independent lab at Northwestern University Medical School (1996) was recruited back to UCSF in 2003. Dr. Brian Shoichet on the web Google Scholar Shoichet Lab Twitter Dr. GPCR Ecosystem Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Dr. GPCR Podcast << Back to podcast list Dr. Stephane Angers About Dr. Stephane Angers Dr. Angers is an expert in the field of signal transduction. He obtained his Ph.D. from the Université de Montréal in 2002 under the guidance of Dr. Michel Bouvier . His thesis work led to the development and application of light energy transfer methodology to study protein-protein interaction and signal transduction. From 2002-2006 he was a Howard Hughes Post-Doctoral Fellow at the University of Washington in Seattle under Dr. Randall T. Moon , where he identified and characterized novel components of the Wnt signaling pathway and a new class of E3 ubiquitin ligases . In October 2006, Dr. Angers established his independent research program in the Department of Pharmaceutical Sciences at the Faculty of Pharmacy and the Department of Biochemistry at the University of Toronto. He is the recipient of the Canada Research Chair in Functional Architecture of Signal Transduction. His research program is developed to understand the signaling mechanisms underlying the Wnt and Hedgehog families of growth factors and their signaling mechanisms in development, adult tissue homeostasis, and human diseases. His pioneer work led to the development of novel antibody molecules blocking and activating the Wnt pathway for the treatment of cancers and regenerative medicine applications. He is the scientific founder of two biotech companies, ModMab Therapeutics , and AntlerA Therapeutics , which are pursuing the clinical development of these molecules. In September 2021, Dr. Angers was named Director of the Donnelly Centre of Cellular and Biomolecular Research at the University of Toronto, an internationally recognized Research Institute bringing together multidisciplinary teams of scientists. Dr. Stephane Angers on the web Angers Lab The Donnelly Centre Twitter Dr. GPCR Ecosystem LinkedIn Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Dr. GPCR Podcast << Back to podcast list Dr. Oliver Hartley About Dr. Oliver Hartley Oliver Hartley is VP for Drug Discovery at Orion Biotechnology . He is the inventor of OB-002 as well as the key technology underlying Orion’s discovery platform. Trained as a biochemist, he completed a PhD in protein engineering (Cambridge, UK) with Sir Gregory Winter (Nobel Prize for Chemistry, 2018). Since then Oliver has worked at the University of Geneva, where his research on peptide engineering and GPCR pharmacology has led to a series of high-profile publications and new intellectual property, and at the Mintaka Foundation for Medical Research with a role as co-founder and Chief Scientific Officer. Dr. Oliver Hartley on the web LinkedIn Orion Biotechnology Dr. GPCR Ecosystem Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Dr. GPCR Podcast << Back to podcast list Dr. Nariman Balenga About Dr. Nariman Balenga "I received my Master’s degree from the University of Tehran, Iran, in 2005 by studying the suitability of nanoparticles as porters of DNA vaccination against allergens in mice. Then I pursued my education in the lab of Dr. Maria Waldhoer at the Medical University of Graz, Austria, and received my Ph.D. in Molecular Medicine in 2010 after studying the orphan atypical cannabinoid receptor, GPR55 and its crosstalk with CB1R and CB2R in endothelial cells and neutrophils. I followed my interest in allergy and GPCRs by joining the lab of Dr. Kirk Druey at NIAID/NIH, where I characterized the role of RGS4 and RGS5 in airway hyperresponsiveness and lung fibrosis in acute and chronic mouse models of allergic asthma. I was fascinated by the multitude of processes that are regulated/dysregulated by GPCRs and RGS proteins in the lungs of patients with asthma. At the height of curiosity, a seemingly naïve idea at the dinner table led to a side project by which I characterized the impact of a fungal allergenic source on the function of airway smooth muscle cells. A fungal serine protease allergen with GPCR-modulating features was discovered as a new biomarker and target in patients with severe asthma. In 2015 I joined the University of Maryland School of Medicine as an Assistant Professor. I studied the function of RGS5, calcium-sensing receptor, and an orphan adhesion GPCR, GPR64/ADGRG2 in parathyroid glands of patients with hyperparathyroidism and their impact on body calcium homeostasis and bone resorption in relevant transgenic mice. In 2021, I joined the Ferring Research Institute of Ferring Pharmaceuticals in San Diego as a scientist." Dr. Nariman Balenga on the web Researchgate Linkedin.com Google Scholar Dr. GPCR Ecosystem Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Dr. GPCR Podcast << Back to podcast list Inês Pinheiro, Monserrat Avila Zozaya & Yamina Berchiche About Inês Pinheiro PharmD by training and Ph.D. candidate in Hartley's lab at the University of Geneva. As a young researcher fascinated by chemokine receptors, molecular pharmacology, drug discovery, and immuno-oncology. Inês Pinheiro on the web LinkedIn University of Geneva Twitter Dr. GPCR Ecosystem About Monserrat Avila Zozaya I am a cell biologist interested in studying GPCRs, especially adhesion GPCRs. Motivated by my scientific passion, I recently started a postdoctoral fellowship to study the role of GPCRs in the mechanisms of pain and its comorbidities. Monserrat Avila Zozaya on the web Antony Boucard Lab Dr. GPCR Ecosystem About Yamina Berchiche Dr. Yamina A. Berchiche is the founder of Dr. GPCR, an ecosystem designed to bring together stakeholders interested in using G-Protein Coupled Receptors (GPCRs), that control virtually everything in the body, as drug targets. The mission of Dr. GPCR is to accelerate GPCR drug discovery by sharing the latest research and technology advances in the field and providing exposure to scientists through the Dr. GPCR podcast. Dr. Berchiche obtained her Master’s and Ph.D. in Biochemistry at the University of Montreal in Canada before training at The Rockefeller University in New York and the National Institutes of Health in Bethesda, Maryland. She developed expertise over the past two decades studying structure/function relationships of GPCRs using live-cell bioluminescence resonance energy transfer (BRET). Her work focused on chemokine receptors, members of the GPCR family that control cell movement in the body. Yamina Berchiche on the web Website LinkedIn Facebook Twitter ResearchGate PubMed Google Scholar Dr. GPCR Ecosystem Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Dr. GPCR Podcast << Back to podcast list Sri Kosuri About Dr. Sri Kosuri Sri is a biologist that has helped build technologies, labs, and companies in synthetic biology, functional genomics, and bioinformatics over the last 20 years. He is passionate about developing more rational ways to understand and engineer biology. Sri is a co-founder at Octant and an Associate Professor at UCLA in the Chemistry and Biochemistry Department. His lab has worked on building large-scale ways of empirically exploring questions in protein biochemistry, human genetic variation, gene regulation, chemical biology, synthetic biology, and functional genomics. Sri previously worked at the Wyss Institute and Harvard, where he built numerous technologies in gene synthesis, DNA information storage, gene editing, and large-scale multiplexed assays. He helped build Gen9, a gene synthesis company, as a member of the SAB and was the first employee of Joule Unlimited, an engineered algal biofuel company. He is a Searle Scholar (2015), NIH New Innovator (2014), and received his ScD in Biological Engineering at MIT and BS in Bioengineering at UC Berkeley. Sri is originally from New Jersey, Philadelphia, and Kansas and was born in North Carolina. He enjoys eating, getting outdoors, and traveling with his wife and two children. Dr. Sri Kosuri on the web Octant Kosuri Lab Twitter LinkedIn Dr. GPCR Ecosystem Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Dr. GPCR Podcast << Back to podcast list Scott Struthers R. Scott Struthers, Ph.D., is our co-founder and has served as our President and Chief Executive Officer since December 2008. Prior to Crinetics, he was senior director and head of endocrinology and metabolism at Neurocrine Biosciences, Inc., from 1998 to 2008. At Neurocrine, he initiated and led the effort to discover and develop orally active, nonpeptide GnRH antagonists, including elagolix. Prior to Neurocrine, from 1995 to 1998, he co-founded ScienceMedia Inc. to develop eLearning solutions for the life sciences and higher education markets. Between 1992 to 1995 he led contract research efforts at Biosym Technologies to develop and apply computational tools for drug discovery. In 2021, Dr. Struthers co-founded and serves as board chair at Radionetics Oncology, a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for oncology indications. In addition, he is a member of the board of directors of the San Diego Entrepreneurs Exchange, a nonprofit organization that provides resources for early-stage start-ups, which he co-founded in [2009.] R. Scott Struthers on the web LinkedIn Google Scholar Crinetics Radionetics Dr. GPCR Ecosystem Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Dr. GPCR Podcast << Back to podcast list Robert Laprairie About Dr. Robert Laprairie Dr. Robert Laprairie is an Associate Professor and the Saskatchewan Research Chair in Drug Discovery and Development in the College of Pharmacy and Nutrition at the University of Saskatchewan. The focus of his research is the molecular pharmacology of cannabinoids and cannabinoid receptors. He was the 2018 and 2021 recipient of the Young Investigator of the Year Awards from the British Pharmacological Society and International Cannabinoid Research Society (ICRS), respectively. In 2019 he became the Director of Education for the Canadian Consortium for the Investigation of Cannabinoids (CCIC) and now also serves as the organization’s President. Dr. Robert Laprairie on the web University of Saskatchewan Twitter Instagram ResearchGate Google Scholar Dr. GPCR Ecosystem Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>

Dr. GPCR Podcast << Back to podcast list Chris Langmead Chris Langmead is Professor, Deputy Director, and Better Medicines Theme Leader of the Neuromedicines Discovery Centre at the Monash Institute of Pharmaceutical Sciences (MIPS), a collaborative venture targeting new medicines development for poorly-treated mental health disorders. He also directs a collaborative neuroscience R&D program with Servier (France) and is the co-founder and CEO of Phrenix Therapeutics, a biotech spin-out from the Neuromedicines Discovery Centre that is developing next-generation therapeutics for schizophrenia. Prior to these roles this he was Head of Pharmacology at Heptares Therapeutics Ltd., a UK-based biotechnology company (2009-2012), where he was responsible all of the company’s discovery biology. He is an acknowledged expert in drug discovery, particularly in the field of psychiatry, where he has led multiple projects into late stage preclinical development, many of which have progressed into clinical trials. These successes enabled the US$400M sale of Heptares Therapeutics Ltd. to the Sosei Group Corporation in 2015. Prior to joining Heptares, Chris was a neuroscience researcher at GlaxoSmithKline, UK (1998-2009). He has a degree and PhD in pharmacology from Queens' College, Cambridge and University College London, respectively, was the youngest person to be elected as a Fellow of the British Pharmacological Society in 2012, and was the recipient of the British Pharmacological Society Novartis Prize in 2017. Chris serves on the editorial boards of the British Journal of Pharmacology, ACS Chemical Neuroscience, ACS Pharmacology & Translational Science and Frontiers in Pharmacology. He is also a corresponding member of NC-IUPHAR. He has published over 70 research articles, reviews and book chapters on drug discovery, which have been cited over 5000 times. Christopher Langmead on the web Monash University T witter Google Scholar Linkedin PubMed Monash Neuromedicines Dr. GPCR Ecosystem Thanks for listening to this podcast episode This short survey will help us understand your needs to bring you exciting and informative content; this short survey should take 5 minutes to fill. Listen and subscribe to where you get your podcasts. << Previous Podcast Episode Next Podcast Episode >>